Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

International Journal of Obesity

Volumn 31, Issue 7, 2007, Pages 1119-1125

  Onat, A ^a,b   Can, G ^b   Hergenc G ^c   Yazici, M ^d   Karabulut, A ^e   Albayrak, S ^d  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^d DUZCE UNIVERSITY   (Turkey)

^e DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Apolipoprotein B; Central obesity; Diabetes mellitus; Dyslipidemia; Hypertension; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERTENSION; INFLAMMATION; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; TIME SERIES ANALYSIS; WAIST CIRCUMFERENCE;

ADULT; AGED; APOLIPOPROTEINS B; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; TURKEY;

EID: 34247607896     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803552     Document Type: Article

References (22)

1. Relimpio F, Losada F, Pumar A, Mangas MA, Morales F, Astorga R. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabet Res Clin Pract 2002; 57: 199-207.
2. Williams K, Sniderman AD, Sattar N, D'Agostino Jr R, Wagenknecht LE, Haffner SM. Comparisons of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108: 2312-2316.
3. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III]. Ann Epidemiol 2004; 14: 686-695.
4. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipo-protein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173-1177.
5. Sattar N, Williams K, Sniderman AD, D'Agostino Jr R, Haffner SM. Comparisons of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study. Circulation 2004; 110: 2687-2693.
6. Faraj M, Messier L, Bastard JP, Tardiff A, Godbout A, Prud'homme D et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006; 49: 1637-1646.
7. Dallongeville J, Cottel D, Arveiler D, Tauber JP, Bingham A, Wagner A et al. The association of metabolic disorders with the metabolic syndrome is different in men and women. Ann Nutr Metab 2004; 48: 43-50.
8. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26: 406-410.
9. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35: 2248-2252.
10. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-292.
11. Onat A, Avci GŞ, Şenocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidem Commun Health 1992; 46: 470-476.
12. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001; 86: 5457-5464.
13. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. The expert committee on the diagnosis and classification of diabetes mellitus. Diabet Care 2003; 26: 3160-3167.
14. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 2001; 285: 2486-2497.
15. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
16. Onat A, Hergenç G, Türkmen S, Yazici M, Sari İ, Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 2006; 55: 445-452.
17. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2006; May 5, E-pub).
18. Sniderman A, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-459.
19. Leino A, Impivaara O, Kaitsaari M, Jarvisalo J. Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Clin Chem 1995; 41: 1633-1636.
20. Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005; 180: 161-169.
21. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033.
22. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PWF et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-29.